To investigate the immunological mechanism underlying the anti-tumor therapeutic effect of combined IKE and anti-PD-L1 antibody treatment enhanced by TIPE2-deficient MDSCs, we checked the distribution of immune cells in the tumor tissues of WT and TIPE2−/− LLC tumor-bearing mice with dual administration. This evidence concerns the gene CD274 and neoplasm.